Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors

Hugo Arias-Pulido, Harriet O. Smith, Nancy E. Joste, Therese Bocklage, Clifford R. Qualls, Allison Chavez, Eric R. Prossnitz, Claire F. Verschraegen

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: Receptors for estrogen (ER) and progesterone (PR) are prognostic indicators for a variety of endocrine tumors including breast and endometrial. This study was conducted to determine if ER and PR expression patterns are predictive of outcome in patients with epithelial ovarian cancer (EOC) or ovarian low malignant potential (LMP) tumors. Methods: ER and PR protein levels were assessed by immunohistochemistry in 45 LMP and 89 EOC samples. Patterns of ER/PR expression (individually and combinations of ER-/PR-, ER+/PR-, ER-/PR+, and ER+/PR+) were correlated with standard prognostic factors of overall survival (OS) in this patient population. Results: For patients with EOC, the 5-year OS per ER-/PR+, ER+/PR-, ER+/PR+, and ER-/PR- expression was 83%, 79%, 61%, and 48%, respectively, and these differences were statistically significant. In multivariate analyses, ER/PR expression patterns were found to be independent predictors of OS, as were the classical prognostic factors of grade, stage, debulking, and chemotherapy response to treatment. In patients with mucinous LMP tumors, ER and PR were absent. Because no LMP patients died of disease during the studied period, no correlation analysis with OS could be performed. Conclusions: Patterns of ER/PR expression provide prognostic information in EOC. Additional studies evaluating hormonal inhibition may help personalize the therapy of patients with ovarian cancer.

Original languageEnglish (US)
Pages (from-to)480-485
Number of pages6
JournalGynecologic Oncology
Volume114
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Progesterone Receptors
Estrogen Receptors
Progesterone
Estrogens
Neoplasms
Survival
Ovarian epithelial cancer
Ovarian Neoplasms
Multivariate Analysis
Immunohistochemistry

Keywords

  • Epithelial ovarian tumors
  • Estrogen receptor
  • Immunohistochemistry
  • Low malignant potential tumors
  • Overall survival
  • Progesterone receptor

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Arias-Pulido, H., Smith, H. O., Joste, N. E., Bocklage, T., Qualls, C. R., Chavez, A., ... Verschraegen, C. F. (2009). Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecologic Oncology, 114(3), 480-485. https://doi.org/10.1016/j.ygyno.2009.05.045

Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. / Arias-Pulido, Hugo; Smith, Harriet O.; Joste, Nancy E.; Bocklage, Therese; Qualls, Clifford R.; Chavez, Allison; Prossnitz, Eric R.; Verschraegen, Claire F.

In: Gynecologic Oncology, Vol. 114, No. 3, 09.2009, p. 480-485.

Research output: Contribution to journalArticle

Arias-Pulido, H, Smith, HO, Joste, NE, Bocklage, T, Qualls, CR, Chavez, A, Prossnitz, ER & Verschraegen, CF 2009, 'Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors', Gynecologic Oncology, vol. 114, no. 3, pp. 480-485. https://doi.org/10.1016/j.ygyno.2009.05.045
Arias-Pulido, Hugo ; Smith, Harriet O. ; Joste, Nancy E. ; Bocklage, Therese ; Qualls, Clifford R. ; Chavez, Allison ; Prossnitz, Eric R. ; Verschraegen, Claire F. / Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. In: Gynecologic Oncology. 2009 ; Vol. 114, No. 3. pp. 480-485.
@article{10ae357f21b6456e9be2744ebeca8865,
title = "Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors",
abstract = "Objective: Receptors for estrogen (ER) and progesterone (PR) are prognostic indicators for a variety of endocrine tumors including breast and endometrial. This study was conducted to determine if ER and PR expression patterns are predictive of outcome in patients with epithelial ovarian cancer (EOC) or ovarian low malignant potential (LMP) tumors. Methods: ER and PR protein levels were assessed by immunohistochemistry in 45 LMP and 89 EOC samples. Patterns of ER/PR expression (individually and combinations of ER-/PR-, ER+/PR-, ER-/PR+, and ER+/PR+) were correlated with standard prognostic factors of overall survival (OS) in this patient population. Results: For patients with EOC, the 5-year OS per ER-/PR+, ER+/PR-, ER+/PR+, and ER-/PR- expression was 83{\%}, 79{\%}, 61{\%}, and 48{\%}, respectively, and these differences were statistically significant. In multivariate analyses, ER/PR expression patterns were found to be independent predictors of OS, as were the classical prognostic factors of grade, stage, debulking, and chemotherapy response to treatment. In patients with mucinous LMP tumors, ER and PR were absent. Because no LMP patients died of disease during the studied period, no correlation analysis with OS could be performed. Conclusions: Patterns of ER/PR expression provide prognostic information in EOC. Additional studies evaluating hormonal inhibition may help personalize the therapy of patients with ovarian cancer.",
keywords = "Epithelial ovarian tumors, Estrogen receptor, Immunohistochemistry, Low malignant potential tumors, Overall survival, Progesterone receptor",
author = "Hugo Arias-Pulido and Smith, {Harriet O.} and Joste, {Nancy E.} and Therese Bocklage and Qualls, {Clifford R.} and Allison Chavez and Prossnitz, {Eric R.} and Verschraegen, {Claire F.}",
year = "2009",
month = "9",
doi = "10.1016/j.ygyno.2009.05.045",
language = "English (US)",
volume = "114",
pages = "480--485",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors

AU - Arias-Pulido, Hugo

AU - Smith, Harriet O.

AU - Joste, Nancy E.

AU - Bocklage, Therese

AU - Qualls, Clifford R.

AU - Chavez, Allison

AU - Prossnitz, Eric R.

AU - Verschraegen, Claire F.

PY - 2009/9

Y1 - 2009/9

N2 - Objective: Receptors for estrogen (ER) and progesterone (PR) are prognostic indicators for a variety of endocrine tumors including breast and endometrial. This study was conducted to determine if ER and PR expression patterns are predictive of outcome in patients with epithelial ovarian cancer (EOC) or ovarian low malignant potential (LMP) tumors. Methods: ER and PR protein levels were assessed by immunohistochemistry in 45 LMP and 89 EOC samples. Patterns of ER/PR expression (individually and combinations of ER-/PR-, ER+/PR-, ER-/PR+, and ER+/PR+) were correlated with standard prognostic factors of overall survival (OS) in this patient population. Results: For patients with EOC, the 5-year OS per ER-/PR+, ER+/PR-, ER+/PR+, and ER-/PR- expression was 83%, 79%, 61%, and 48%, respectively, and these differences were statistically significant. In multivariate analyses, ER/PR expression patterns were found to be independent predictors of OS, as were the classical prognostic factors of grade, stage, debulking, and chemotherapy response to treatment. In patients with mucinous LMP tumors, ER and PR were absent. Because no LMP patients died of disease during the studied period, no correlation analysis with OS could be performed. Conclusions: Patterns of ER/PR expression provide prognostic information in EOC. Additional studies evaluating hormonal inhibition may help personalize the therapy of patients with ovarian cancer.

AB - Objective: Receptors for estrogen (ER) and progesterone (PR) are prognostic indicators for a variety of endocrine tumors including breast and endometrial. This study was conducted to determine if ER and PR expression patterns are predictive of outcome in patients with epithelial ovarian cancer (EOC) or ovarian low malignant potential (LMP) tumors. Methods: ER and PR protein levels were assessed by immunohistochemistry in 45 LMP and 89 EOC samples. Patterns of ER/PR expression (individually and combinations of ER-/PR-, ER+/PR-, ER-/PR+, and ER+/PR+) were correlated with standard prognostic factors of overall survival (OS) in this patient population. Results: For patients with EOC, the 5-year OS per ER-/PR+, ER+/PR-, ER+/PR+, and ER-/PR- expression was 83%, 79%, 61%, and 48%, respectively, and these differences were statistically significant. In multivariate analyses, ER/PR expression patterns were found to be independent predictors of OS, as were the classical prognostic factors of grade, stage, debulking, and chemotherapy response to treatment. In patients with mucinous LMP tumors, ER and PR were absent. Because no LMP patients died of disease during the studied period, no correlation analysis with OS could be performed. Conclusions: Patterns of ER/PR expression provide prognostic information in EOC. Additional studies evaluating hormonal inhibition may help personalize the therapy of patients with ovarian cancer.

KW - Epithelial ovarian tumors

KW - Estrogen receptor

KW - Immunohistochemistry

KW - Low malignant potential tumors

KW - Overall survival

KW - Progesterone receptor

UR - http://www.scopus.com/inward/record.url?scp=67651149472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651149472&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.05.045

DO - 10.1016/j.ygyno.2009.05.045

M3 - Article

C2 - 19560192

AN - SCOPUS:67651149472

VL - 114

SP - 480

EP - 485

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -